PMID- 10936179
OWN - NLM
STAT- MEDLINE
DCOM- 20000912
LR  - 20190630
IS  - 0022-3042 (Print)
IS  - 0022-3042 (Linking)
VI  - 75
IP  - 3
DP  - 2000 Sep
TI  - 2-Deoxy-D-glucose prevents and nicotinamide potentiates 3, 
      4-methylenedioxymethamphetamine-induced serotonin neurotoxicity.
PG  - 982-90
AB  - Neurotoxicity induced by different substituted amphetamines has been associated 
      with the exhaustion of intracellular energy stores. Accordingly, we examined the 
      influence of 2-deoxy-D-glucose (2-DG), a competitive inhibitor of glucose uptake 
      and metabolism, and nicotinamide, an agent that improves energy metabolism, on 3, 
      4-methylenedioxymethamphetamine (MDMA)-induced 5-hydroxytryptamine (5-HT; 
      serotonin) deficits. Administration of MDMA (15 mg/kg i.p.) produced a 
      significant hyperthermia, whereas 2-DG caused a profound hypothermia that lasted 
      throughout the experiment. When MDMA was given to 2-DG-treated rats, an immediate 
      but transient hyperthermia occurred and was followed by a return to hypothermia. 
      2-DG had no effect on 5-HT concentrations in the frontal cortex, hippocampus, and 
      striatum but prevented the neurotoxicity induced by MDMA. When rats were injected 
      with 2-DG/MDMA and were warmed to prevent hypothermia, the protection afforded by 
      2-DG was abolished. Nicotinamide had no effect on body temperature of the rats, 
      and the hyperthermia induced by the nicotinamide/MDMA treatment was similar to 
      that of the saline/MDMA-treated rats. However, the long-term 5-HT deficits 
      induced by MDMA were potentiated by nicotinamide in all the brain regions 
      examined. Finally, no change on ATP concentrations in the frontal cortex, 
      hippocampus, and striatum was observed up to 3 h after a single dose of MDMA. 
      These results suggest that an altered energy metabolism is not the main cause of 
      the neurotoxic effects induced by MDMA.
FAU - Hervias, I
AU  - Hervias I
AD  - Department of Pharmacology, University of Navarra Medical School, Pamplona, 
      Spain.
FAU - Lasheras, B
AU  - Lasheras B
FAU - Aguirre, N
AU  - Aguirre N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Neurochem
JT  - Journal of neurochemistry
JID - 2985190R
RN  - 0 (Carrier Proteins)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Membrane Transport Proteins)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Neurotoxins)
RN  - 0 (Serotonin Plasma Membrane Transport Proteins)
RN  - 0 (Slc6a4 protein, rat)
RN  - 102-32-9 (3,4-Dihydroxyphenylacetic Acid)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 333DO1RDJY (Serotonin)
RN  - 41VRH5220H (Paroxetine)
RN  - 54-16-0 (Hydroxyindoleacetic Acid)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
RN  - X77S6GMS36 (Homovanillic Acid)
SB  - IM
MH  - 3,4-Dihydroxyphenylacetic Acid/metabolism
MH  - Adenosine Triphosphate/metabolism
MH  - Animals
MH  - Body Temperature/drug effects
MH  - Brain/drug effects/*metabolism
MH  - Carrier Proteins/metabolism
MH  - Corpus Striatum/drug effects/metabolism
MH  - Dopamine/metabolism
MH  - Drug Synergism
MH  - Frontal Lobe/drug effects/metabolism
MH  - Hippocampus/drug effects/metabolism
MH  - Homovanillic Acid/metabolism
MH  - Hydroxyindoleacetic Acid/metabolism
MH  - Hypothermia/chemically induced
MH  - Male
MH  - Membrane Glycoproteins/metabolism
MH  - *Membrane Transport Proteins
MH  - N-Methyl-3,4-methylenedioxyamphetamine/antagonists & inhibitors/*toxicity
MH  - *Nerve Tissue Proteins
MH  - Neurotoxins/toxicity
MH  - Niacinamide/*pharmacology
MH  - Organ Specificity
MH  - Paroxetine/pharmacokinetics
MH  - Rats
MH  - Rats, Wistar
MH  - Serotonin/*metabolism
MH  - Serotonin Plasma Membrane Transport Proteins
EDAT- 2000/08/11 11:00
MHDA- 2000/09/19 11:01
CRDT- 2000/08/11 11:00
PHST- 2000/08/11 11:00 [pubmed]
PHST- 2000/09/19 11:01 [medline]
PHST- 2000/08/11 11:00 [entrez]
AID - 10.1046/j.1471-4159.2000.0750982.x [doi]
PST - ppublish
SO  - J Neurochem. 2000 Sep;75(3):982-90. doi: 10.1046/j.1471-4159.2000.0750982.x.